Please assess the completion status of the following clinical trial:

Trial Title: Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be undergoing their first cardiac allograft transplant.~* Male or female must be less than or equal to 18 years of age.~* Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to transplantation. The sensitivity must be equal to at least 50 mIU/ml. (Urine test is allowed in addition to serum test in patients where serum results are delayed.)~* Women of childbearing potential must use two reliable forms of contraception simultaneously.~* Effective contraception must be used before beginning study drug therapy, and for 4 months following discontinuation of study drug therapy.~* Patients and/or their guardians must be willing and be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.~Exclusion Criteria:~* Patients with a history of hypersensitivity reactions to any of the constituents of the Zenapax(R) preparation or having had hypersensitivity reactions to human or murine immune globulin preparations in the past.~* Women lactating, pregnant or of childbearing potential not using, or who are unwilling to use two reliable forms of contraception simultaneously during the study~* History of a psychological illness or condition which would interfere with the patient's ability to understand the requirements of the study~* White blood count \< 2500/mm\^3, platelets \< 50,000 /mm\^3 or hemoglobin \< 6 g/dL.~* HIV-1 infection or the presence of positive hepatitis B surface antigen (HBsAg) or chronic hepatitis C.~* Active peptic ulcer disease~* Severe diarrhea or other gastrointestinal disorders which might interfere with the ability to absorb oral medication~* Malignancies within the past 5 years, excluding skin carcinomas (basal or squamous cell) that have been adequately treated~* Patients who have received within the past 30 days or require concomitant treatment with other investigational drugs or immunosuppressive medications that are prohibited for this study~* Inability to start microemulsion form of cyclosporine within 72 hours

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).